[go: up one dir, main page]

CO5170528A1 - Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8 - Google Patents

Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8

Info

Publication number
CO5170528A1
CO5170528A1 CO00038191A CO00038191A CO5170528A1 CO 5170528 A1 CO5170528 A1 CO 5170528A1 CO 00038191 A CO00038191 A CO 00038191A CO 00038191 A CO00038191 A CO 00038191A CO 5170528 A1 CO5170528 A1 CO 5170528A1
Authority
CO
Colombia
Prior art keywords
alkyl
cr8r8
alkenyl
heteroaryl
optionally substituted
Prior art date
Application number
CO00038191A
Other languages
English (en)
Inventor
Michael R Palovich
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of CO5170528A1 publication Critical patent/CO5170528A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/08—1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/18—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un compuesto de la fórmula (I):<EMI FILE="00038191_1" ID="1" IMF=JPEG >donde:R es OH, SH, NHSO2Rd;Rd es NR6R7, alquilo, aril-alquilo C1-4, aril-alquenilo C2-4, heteroarilo, heteroaril-alquilo C1-4, heteroaril-alquenilo C2-4, radical heterocíclico, heterociclil-alquilo C1-4, donde los anillos arilo, heteoarilo y heterocíclico pueden estar opcionalmente sustituidos;R6 y R7 son, independientemente, hidrógeno, o un grupo alquilo C1-4, o R6 y R7, junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros, cuyo anillo puede contener opcionalmente un heteroátomo adicional que se selecciona entre oxígeno, nitrógeno o azufre, y cuyo anillo puede estar opcionalmente sustituido;R1 se selecciona, independientemente, entre hidrógeno, halógeno, nitro, ciano, alquilo C1-10 halosustituido, alquilo C1-10, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 halosustituido, azida, (CR8R8)qS(O)tR4, hidroxi, hidroxi-alquilo C1-4, arilo, aril-alquilo C1-4, ariloxi, aril-alquiloxi C1-4, heteroarilo, heteroarilalquilo, radical heterocíclico, heterociclil-alquilo C1-4, heteroaril-alquiloxi C1-4, aril-alquenilo C2-10, heteroaril-alquenilo C2-10, heterociclil-alquenilo C2-10, (CR8R8)qNR4R5, alquenil C2-10-C(O)NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11, (CR8R8)qC(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)qNHS(O)2R17, (CR8R8)qS(O)2NR4R5, o dos restos R1 juntos pueden formar O-(CH2)sO- o un anillo insaturado de 5 a 6 miembros;q es 0, o un número entero que tiene un valor de 1 a 10; t es 0, o un número entero que tiene un valor de 1 ó 2;s es un número entero que tiene un valor de 1 a 3;R4 y R5 son, independientemente, hidrógeno, alquilo C1-4 opcionalmente sustituido, arilo opcionalmente sustituido, (aril opcionalmente sustituido)-alquilo C1-4, heteroarilo opcionalmente sustituido, (heteroaril opcionalmente sustituido)-alquilo C1-4, radical heterocíclico, heterociclil-alquilo C1-4, o R4 y R5, junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros que puede contener opcionalmente un heteroátomo adicional seleccionado entre oxígeno, nitrógeno o azufre; ...
CO00038191A 1999-05-28 2000-05-24 Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8 CO5170528A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13666599P 1999-05-28 1999-05-28

Publications (1)

Publication Number Publication Date
CO5170528A1 true CO5170528A1 (es) 2002-06-27

Family

ID=22473833

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00038191A CO5170528A1 (es) 1999-05-28 2000-05-24 Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8

Country Status (20)

Country Link
EP (1) EP1180025A4 (es)
JP (1) JP2003500443A (es)
KR (1) KR20020016806A (es)
CN (1) CN1352554A (es)
AR (1) AR029361A1 (es)
AU (1) AU766999B2 (es)
BR (1) BR0010863A (es)
CA (1) CA2374295A1 (es)
CO (1) CO5170528A1 (es)
CZ (1) CZ20014246A3 (es)
HK (1) HK1045256A1 (es)
HU (1) HUP0201302A3 (es)
IL (1) IL146053A0 (es)
MX (1) MXPA01012267A (es)
NO (1) NO20015774L (es)
NZ (1) NZ514728A (es)
PL (1) PL351947A1 (es)
TR (1) TR200103354T2 (es)
WO (1) WO2000072840A1 (es)
ZA (1) ZA200109627B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1413302A3 (en) * 1999-07-21 2004-05-12 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of pain
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
EP1202718A2 (en) * 1999-07-21 2002-05-08 Kadmus Pharmaceuticals, Inc. Substituted guanidines for the treatment of cancer and pain
EP1395548A1 (en) 2001-02-26 2004-03-10 4Sc Ag Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
DE10109204A1 (de) * 2001-02-26 2002-09-19 4Sc Ag Verbindungen zur Behandlung von Protozoen-Erkrankungen
BRPI0409957A (pt) 2003-05-01 2006-04-25 Hoffmann La Roche imidazolin-2-ilaminofenil amidas
CN101531621B (zh) * 2009-04-14 2012-08-15 厦门康奥克科技有限公司 一种胍类化合物的制备方法
US11459293B2 (en) * 2017-10-27 2022-10-04 Immunebridge Inc. Compositions and methods of making expanded hematopoietic stem cells using derivatives of fluorene

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US605977A (en) * 1898-06-21 Bruno richard seifert
US1953494A (en) * 1926-08-26 1934-04-03 Ig Farbenindustrie Ag Process of preparing substituted guanidines
US3914306A (en) * 1972-09-22 1975-10-21 Rorer Inc William H Guanidines
US5696290A (en) * 1994-09-12 1997-12-09 Monsanto Company Synthesis of penta-substituted guanidines
WO1996025157A1 (en) * 1995-02-17 1996-08-22 Smithkline Beecham Corporation Il-8 receptor antagonists
AR008290A1 (es) * 1996-08-15 1999-12-29 Smithkline Beecham Corp Nuevos compuestos que contienen guanidina utiles como antagonistas de los receptores de il-8, composiciones farmaceuticas que los contienenprocedimiento para la preparacion de dichos compuestos y procedimiento para la preparacion de intermediarios.
WO2000072800A2 (en) * 1999-05-28 2000-12-07 Smithkline Beecham Corporation Il-8 receptor antagonists
UY26627A1 (es) * 2000-03-24 2001-09-28 Smithkline Beecham Corp Antagonistas de receptores de il-8

Also Published As

Publication number Publication date
BR0010863A (pt) 2002-02-19
ZA200109627B (en) 2002-11-28
AU766999B2 (en) 2003-10-30
EP1180025A1 (en) 2002-02-20
CZ20014246A3 (cs) 2002-05-15
HUP0201302A2 (hu) 2002-12-28
TR200103354T2 (tr) 2002-06-21
PL351947A1 (en) 2003-07-14
HK1045256A1 (zh) 2002-11-22
JP2003500443A (ja) 2003-01-07
MXPA01012267A (es) 2002-07-30
NZ514728A (en) 2004-04-30
CN1352554A (zh) 2002-06-05
NO20015774D0 (no) 2001-11-27
AU5169000A (en) 2000-12-18
WO2000072840A1 (en) 2000-12-07
HUP0201302A3 (en) 2003-02-28
AR029361A1 (es) 2003-06-25
IL146053A0 (en) 2002-07-25
KR20020016806A (ko) 2002-03-06
CA2374295A1 (en) 2000-12-07
EP1180025A4 (en) 2002-08-28
NO20015774L (no) 2001-11-27

Similar Documents

Publication Publication Date Title
CO5280059A1 (es) Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones
CO5170514A1 (es) Antagonistas de los receptores de la il-8 nistas del receptor de la il-8
CO4970747A1 (es) Antagonistas de receptores de il-8
CO5251467A1 (es) Derivados de piperazina
CO4940442A1 (es) Derivados de 4-bromo o 4-yodo fenilamino acido benzhidroxamico
AR076896A2 (es) Un metodo para inhibir la polimerizacion prematura de monomeros etilenicamente insaturados
AR032398A1 (es) Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion
CO5140088A1 (es) Derivados de fenil y piridinil amida, su procedimiento de sintesis y composiciones farmaceuticas que los contienen
CO5140087A1 (es) Derivados de 3-fenil-piridina su procedimiento de sintesis y medicamentos que los contienen
ATE369855T1 (de) Modulatoren von peroxisome proliferator- aktivierten rezeptoren
CO5170528A1 (es) Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
CO5601012A2 (es) Compuestos que modulan la actividad de ppar
ES8607970A1 (es) Un procedimiento para la obtencion de derivados de hexahidro-3-oxo-piridinas.
CO4890843A1 (es) Antagonistas de los receptores de il-8 de il-8
CO4990929A1 (es) Compuestos de difenilurea sustituidos con sulfonamidas como antagonistas de los receptores de il-8
CO5310550A1 (es) Nuevo derivado de androstano antiinflamatorio, su polimorfo, sus formas cristalinas solvatadas, composiciones farmaceutias, proceso para prepararlo, intermediario
NO20004090L (no) Kjemiske forbindelser
AR033803A1 (es) Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas
CO5031286A1 (es) Compuestos de ciano guanadina como antagonistas de los receptores de il-8 y metodo de preparacion
MX9801410A (es) Nuevas n-aminoalquilfluorencarboxamidas; una nueva clase de ligandos especificos del subtipo del receptor de la dopamina.
CO5271716A1 (es) Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
CO5200760A1 (es) Antagonistas del receptor de la il-8 ceptor il-8
ES2179005T3 (es) Compuesto de cromeno.
AR027218A1 (es) Inhibicion de polimerizacion de monomeros insaturados

Legal Events

Date Code Title Description
FC Application refused